24/7 Market News Snapshot 12 May, 2025 – Harvard Bioscience Inc (NASDAQ:HBIO)
DENVER, Colo., 12 May, 2025 (www.247marketnews.com) – (NASDAQ:HBIO) are discussed in this article.
Harvard Bioscience Inc. (HBIO) has begun trading at $0.37, currently positioned at $0.348, reflecting a decline of approximately 10.48% from the previous session’s close of $0.315. This fluctuation indicates increasing market interest, as evidenced by a significant trading volume of 10.37 million shares, which suggests potential volatility and heightened activity among investors. Traders may find opportunities in the current landscape, although the stock’s price exhibits resistance around the $0.37 mark. Investors should closely observe support levels near $0.315, as crossing below this threshold may heighten selling pressure and impact market sentiment.
In a recent financial update, Harvard Bioscience reported revenues of $21.8 million for the first quarter of 2025, showcasing steady performance amidst seasonal trends and uncertainties tied to NIH funding and geopolitical factors. Jim Green, the Company’s Chairman and CEO, expressed confidence in their innovation strategy, particularly highlighting the positive momentum for the MeshMEA™ organoid systems, which are gaining traction within academic and biopharma circles. Furthermore, the introduction of the SoHo™ telemetry systems has received favorable feedback, reaffirming the Company’s dedication to advancements in life sciences.
Although the Company registered a net loss of $(50.3) million—primarily due to a goodwill impairment of $(48.0) million—the improvement in operational cash flow, which reached $3.0 million compared to $1.4 million in the previous year, signals resilience. To enhance financial stability, Harvard Bioscience plans to implement strategic cost-saving measures projected to yield around $1 million in quarterly savings, effective from the second quarter of 2025.
Looking forward, the Company estimates second-quarter revenues between $18 million and $20 million, with gross margins anticipated between 55% and 57%. Committed to transparency and operational efficiency, Harvard Bioscience continues to play a pivotal role in advancing life sciences research.